

SCH 58261: A potent and selective non-xanthine A_{2A} adenosine receptor antagonist


Adenosine (Prod. No. [A 9251](#)) acts as a modulator of neuronal activity through its interaction with four receptor subtypes referred to as A₁, A_{2A}, A_{2B} and A₃. Activation of these receptors can protect neurons from damage caused by ischemia and excitotoxins [1]. Adenosine also has the ability to reduce the release of several neurotransmitters, including **glutamate** (Prod. No. [G 1251](#)).

Sigma-RBI is now pleased to offer **SCH 58261** (Prod. No. [S 4568](#)), a potent and selective A_{2A} adenosine receptor antagonist. This compound displayed affinity in the low nanomolar range at A_{2A} adenosine receptors using [³H]-CHA and [³H]-CGS 21680 as radioligands as well as 50 to 100-fold A_{2A} vs A₁ selectivity in rat and bovine brain tissues [2]. In functional assays, SCH 58261 competitively blocks the effects induced by **CGS 21680** (Prod. No. [C-141](#)), an A_{2A} selective agonist, with pA₂ values of 7.9 in a rabbit platelet aggregation assay and 9.5 in a porcine coronary artery relaxation assay. The compound failed to block responses mediated by A_{2B} adenosine receptors in similar studies [2].

SCH 58261 has been shown to protect against neuronal cell death produced by ischemia or excitotoxicity [1]. Thus, when administered to rats that had undergone middle cerebral artery occlusion, SCH 58261 suppressed turning behavior and significantly reduced the release of glutamate, **aspartate** (Prod. No. [A 9256](#)), **GABA** (Prod. No. [A 2129](#)), adenosine and **taurine** (Prod. No. [T 0625](#))

[3]. These results suggest a neuroprotective effect of this compound. In another study, the role of A₁ and A_{2A} adenosine receptors in controlling the rise of extracellular glutamate during ischemia was investigated by monitoring the effects of selective A₁ and A_{2A} adenosine receptor antagonists on ischemia-evoked glutamate release in rat cerebrocortical slices. SCH 58261 decreased [³H]-D-aspartate or endogenous glutamate efflux (50% and 55% inhibition, respectively) displaying EC₅₀ values of 14.9 nM and 7.6 nM, respectively. This study also indicates that SCH 58261 is effective if administered during ischemia [4].

SCH 58261 is therefore an important new tool for studying A_{2A} adenosine receptors and their role in various diseases.



SCH 58261
(Prod. No. [S 4568](#))

References

1. Stone, T.W., *Adv. Exp. Med. Biol.*, **513**, 249-280 (2002).
2. Zocchi, C., et al., *J. Pharmacol. Exp. Ther.*, **276**, 398-404 (1996).
3. Melani, A., et al., *Brain Res.*, **959**, 243-250 (2003).
4. Marcoli, M., et al., *Neuropharmacology*, **45**, 201-210 (2003).